Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery

NCT07500376 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-03-15
Last updated
2026-07-24

Condition(s) studied

Lung Cancer (Non-Small Cell)SarcopeniaMalnutrition Severe

Investigational drug(s) / intervention(s)

Observational Assessment

Observational Assessment: Participants will undergo standard preoperative clinical evaluation including nutritional assessment, laboratory measurements, and imaging-based body composition analysis as part of routine care. No experimental intervention or treatment is administered. All data are collected observationally without influencing clinical management.

Study summary

This prospective observational cohort study aims to evaluate the prognostic value of multimodal nutritional status and sarcopenia assessment in patients undergoing lung cancer surgery. Postoperative complications, mortality, and prolonged hospital stay remain major clinical concerns in thoracic surgery. Although malnutrition and sarcopenia are recognized as important determinants of surgical outcomes, their combined and multidimensional evaluation has not been sufficiently studied.

Adult patients undergoing anatomical lung resection for primary lung cancer will be included. Nutritional status will be assessed using serum biomarkers, inflammatory indices, and validated clinical nutritional scores. Sarcopenia will be evaluated using computed tomography-based muscle mass and density measurements, as well as ultrasonographic muscle thickness.

These parameters will be analyzed in relation to postoperative complications, intensive care unit (ICU) requirement, length of hospital stay, and mortality. Multivariable analyses will be performed to identify independent predictors, and a combined risk stratification model will be developed.

This study aims to improve preoperative risk assessment and to support personalized perioperative management strategies, including identification of patients who may benefit from targeted nutritional optimization and prehabilitation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Patients undergoing anatomical lung resection (lobectomy or segmentectomy) for primary lung cancer * Availability of preoperative thoracic computed tomography (CT) within 30 days before surgery * Completion of preoperative nutritional assessment and ultrasonographic muscle measurements * Ability to provide written informed consent Exclusion Criteria: * Receipt of neoadjuvant chemotherapy, immunotherapy, or radiotherapy * Emergency surgery * Pneumonectomy * Combined resection of another organ during the same procedure * Inadequate or non-evaluable imaging or measurement data * Immunosuppressive therapy or presence of advanced/metastatic disease * Significant thoracic deformity or prior conditions interfering with muscle measurements * Refusal or inability to provide informed consent

Primary outcome measure(s)

  • Postoperative complications (30-day, Clavien-Dindo classification) — Within 30 days after surgery
    Occurrence of postoperative complications within 30 days after surgery, classified according to the Clavien-Dindo classification system. Major complications are defined as Grade III or higher. This outcome will be analyzed as both overall complication rate and major complication rate.

Trial sites (1)

FacilityCityRegionStatus
Ondokuz Mayis University Faculty of Medicine, Department of Thoracic Surgery Samsun Samsun Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07500376 on ClinicalTrials.gov ↗ ← All trials in Turkey